NCT01467518 - Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Infections, Human Immunodeficiency Virus and Hepatitis

Interventions

DRUG

Dolutegravir

Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.

DRUG

Methadone

Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.

Trial Locations (1)

GSK Investigational Site, Toronto